FAM227B: A Promising Drug Target / Biomarker (G196951)

Target Name: FAM227B

NCBI ID: G196951

FAM227B

FAM227B: A Promising Drug Target / Biomarker

FAM227B is a gene that encodes a protein known as FAM227B, which is a key regulator of the sprouting angiogenesis pathway. This pathway is critical for the development and maintenance of tissues such as blood vessels, hair follicles, and the nervous system. FAM227B plays a crucial role in the regulation of angiogenesis by promoting the sprouting angiogenesis pathway and inhibiting the endothelial-mesenchymal transition (EMT).

The sprouting angiogenesis pathway is a process that is essential for the formation of new blood vessels during development and wound healing. This pathway involves the recruitment of progenitor cells from the bone marrow to the site of the injury or inflammation, where they differentiate into functional blood vessels. The sprouting angiogenesis pathway is also critical for the formation of new capillaries during tissue repair.

FAM227B is a key regulator of the sprouting angiogenesis pathway. It encodes a protein that is involved in the regulation of angiogenesis by promoting the sprouting angiogenesis pathway and inhibiting the endothelial-mesenchymal transition (EMT). The sprouting angiogenesis pathway is critical for the development and maintenance of tissues such as blood vessels, hair follicles, and the nervous system. FAM227B plays a crucial role in the regulation of angiogenesis by promoting the sprouting angiogenesis pathway and inhibiting the endothelial-mesenchymal transition (EMT).

FAM227B is a transmembrane protein that is expressed in a variety of tissues, including the brain, heart, and blood vessels. It is primarily localized to the endothelial cell, where it is involved in the regulation of angiogenesis. FAM227B is a key regulator of the sprouting angiogenesis pathway by promoting the sprouting angiogenesis pathway and inhibiting the endothelial-mesenchymal transition (EMT).

The sprouting angiogenesis pathway is a critical pathway for the formation of new blood vessels during development and wound healing. This pathway involves the recruitment of progenitor cells from the bone marrow to the site of the injury or inflammation, where they differentiate into functional blood vessels. The sprouting angiogenesis pathway is also critical for the formation of new capillaries during tissue repair.

FAM227B is a key regulator of the sprouting angiogenesis pathway by promoting the sprouting angiogenesis pathway and inhibiting the endothelial-mesenchymal transition (EMT). The sprouting angiogenesis pathway is critical for the development and maintenance of tissues such as blood vessels, hair follicles, and the nervous system. FAM227B plays a crucial role in the regulation of angiogenesis by promoting the sprouting angiogenesis pathway and inhibiting the endothelial-mesenchymal transition (EMT).

FAM227B is a transmembrane protein that is expressed in a variety of tissues, including the brain, heart, and blood vessels. It is primarily localized to the endothelial cell, where it is involved in the regulation of angiogenesis. FAM227B is a key regulator of the sprouting angiogenesis pathway by promoting the sprouting angiogenesis pathway and inhibiting the endothelial-mesenchymal transition (EMT).

The sprouting angiogenesis pathway is a critical pathway for the formation of new blood vessels during development and wound healing. This pathway involves the recruitment of progenitor cells from the bone marrow to the site of the injury or inflammation, where they differentiate into functional blood vessels. The sprouting angiogenesis pathway is also critical for the formation of new capillaries during tissue repair.

FAM227B is a key regulator of the sprouting angiogenesis pathway by promoting the sprouting angiogenesis pathway and inhibiting the endothelial-mes

Protein Name: Family With Sequence Similarity 227 Member B

The "FAM227B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM227B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets